Evidence map›Paper›PMID 28523271›Full record

ArticleFrontiers in molecular biosciences2017

The Protein Chaperone ClpX Targets Native and Non-native Aggregated Substrates for Remodeling, Disassembly, and Degradation with ClpP.

Christopher J LaBreck, Shannon May, Marissa G Viola, Joseph Conti, Jodi L Camberg

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Development of heat-shock resistance inApplied and environmental microbiology · 2023
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Polyphasic Identification and Genomic Insights ofFrontiers in microbiology · 2022
    Article
  15. Article
  16. Staphylococcal ClpXP protease targets the cellular antioxidant system to eliminate fitness-compromised cells in stationary phase.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Christopher J LaBreckDepartment of Cell and Molecular Biology, University of Rhode IslandKingston, RI, USA.
Shannon MayDepartment of Cell and Molecular Biology, University of Rhode IslandKingston, RI, USA.
Marissa G ViolaDepartment of Cell and Molecular Biology, University of Rhode IslandKingston, RI, USA.
Joseph ContiDepartment of Cell and Molecular Biology, University of Rhode IslandKingston, RI, USA.
Jodi L CambergDepartment of Cell and Molecular Biology, University of Rhode IslandKingston, RI, USA.
University of Rhode Island · US

Funding

Training CoreP20GM103430 · NIGMS · UNIVERSITY OF RHODE ISLAND · PI Bongsup P Cho · 2012 to 2026
$63.6M
NIGMS NIH HHS P20 GM103430
6 · The paper itself

Abstract

ClpX is a member of the Clp/Hsp100 family of ATP-dependent chaperones and partners with ClpP, a compartmentalized protease, to degrade protein substrates bearing specific recognition signals. ClpX targets specific proteins for degradation directly or with substrate-specific adaptor proteins. Native substrates of ClpXP include proteins that form large oligomeric assemblies, such as MuA, FtsZ, and Dps in

Indexed as

AAA+ATPasedisaggregationproteolysisunfoldase

Identifiers

PMID28523271
PMCPMC5415555
OpenAlexW2611002955

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.